Latest news with #ALUR
Yahoo
29-05-2025
- Business
- Yahoo
Allurion Technologies Inc. (ALUR) Returns to France with 12.2% Weight Loss, 6.6% Muscle Gain Results
Allurion Technologies Inc. (NYSE:ALUR), a leader in innovative weight loss solutions, is set to resume patient treatments in France next month following the successful resumption of product shipments. This announcement comes on the heels of new clinical data presented at the meeting in Saint-Etienne, France. 15 States with the Best Healthcare in the US The study evaluated 1,962 French patients using Allurion Technologies Inc. (NYSE:ALUR)'s Program, which features a swallowable gastric balloon and AI-powered health coaching. Over just four months, participants achieved an average 12.2% reduction in total body weight. Notably, muscle mass as a percentage of body weight increased by 6.6%, and lean body mass rose by 6.0%. Fat mass and visceral fat index dropped by 11% and 12.2%, respectively. These results suggest significant improvements in metabolic health. Dr. Thibaut Coste, a leading bariatric surgeon, highlighted the importance of losing weight while increasing muscle mass for sustainable, long-term health benefits. Dr. Shantanu Gaur, Allurion Technologies Inc. (NYSE:ALUR)'s Founder and CEO, expressed enthusiasm about returning to the French market, emphasizing the company's commitment to metabolically healthy weight loss and the potential for continued success in France. While we acknowledge the potential of ALUR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ALUR and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28-05-2025
- Business
- Yahoo
Allurion Technologies Inc. (ALUR) Returns to France with 12.2% Weight Loss, 6.6% Muscle Gain Results
Allurion Technologies Inc. (NYSE:ALUR), a leader in innovative weight loss solutions, is set to resume patient treatments in France next month following the successful resumption of product shipments. This announcement comes on the heels of new clinical data presented at the meeting in Saint-Etienne, France. 15 States with the Best Healthcare in the US The study evaluated 1,962 French patients using Allurion Technologies Inc. (NYSE:ALUR)'s Program, which features a swallowable gastric balloon and AI-powered health coaching. Over just four months, participants achieved an average 12.2% reduction in total body weight. Notably, muscle mass as a percentage of body weight increased by 6.6%, and lean body mass rose by 6.0%. Fat mass and visceral fat index dropped by 11% and 12.2%, respectively. These results suggest significant improvements in metabolic health. Dr. Thibaut Coste, a leading bariatric surgeon, highlighted the importance of losing weight while increasing muscle mass for sustainable, long-term health benefits. Dr. Shantanu Gaur, Allurion Technologies Inc. (NYSE:ALUR)'s Founder and CEO, expressed enthusiasm about returning to the French market, emphasizing the company's commitment to metabolically healthy weight loss and the potential for continued success in France. While we acknowledge the potential of ALUR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ALUR and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None.
Yahoo
14-05-2025
- Business
- Yahoo
Allurion Technologies, Inc. (ALUR) Q1 Earnings Beat Estimates
Allurion Technologies, Inc. (ALUR) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of a loss of $1.53 per share. This compares to earnings of $2.75 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 128.10%. A quarter ago, it was expected that this company would post a loss of $5 per share when it actually produced a loss of $7, delivering a surprise of -40%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Allurion Technologies, Inc. , which belongs to the Zacks Medical - Products industry, posted revenues of $5.58 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 2.11%. This compares to year-ago revenues of $9.39 million. The company has not been able to beat consensus revenue estimates over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Allurion Technologies, Inc. Shares have lost about 78.1% since the beginning of the year versus the S&P 500's gain of 0.1%. While Allurion Technologies, Inc. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Allurion Technologies, Inc. Mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$1.15 on $6.05 million in revenues for the coming quarter and -$4.19 on $28.6 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 31% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, Medtronic (MDT), is yet to report results for the quarter ended April 2025. The results are expected to be released on May 21. This medical device company is expected to post quarterly earnings of $1.58 per share in its upcoming report, which represents a year-over-year change of +8.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Medtronic's revenues are expected to be $8.81 billion, up 2.6% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Allurion Technologies, Inc. (ALUR) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
